Innate Pharma (IPHYF) Projected to Post Earnings on Wednesday

Innate Pharma (OTCMKTS:IPHYF) is anticipated to release its resultson Wednesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.3524) per share and revenue of $5.7550 million for the quarter.

Innate Pharma Stock Performance

Shares of IPHYF opened at $1.50 on Wednesday. Innate Pharma has a 52 week low of $1.37 and a 52 week high of $1.50. The firm’s 50-day simple moving average is $1.72 and its 200 day simple moving average is $1.95.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.